Drugs & Pharmaceuticals

“It’s ironic that I am being accused of a conflict of interest by these doctors when, as you are about to see, some of them have their own conflict of interest issues--and some integrity ones also.” 

It's more than a little disturbing that I have to be writing about this, but in light of Vladimir Putin's most recent threat to use nu

Join Cameron English and  Dr. Chuck Dinerstein on Episode 97 of the Science Dispatch podcast as they discuss:

It's not easy being in pain these days. Tylenol is virtually useless, something you probably already know.

Zantac’s manufacturers were on a roll. Their defense had exacted a spate of favorable decisions and jury verdicts. Yet, on October 9, Glaxo Smith Kline (GSK) suddenly settled 93% of the remaining cases – for 2.2 billion dollars.

It was only a matter of time. It's not just our opioid laws that are a bona fide mess.

Join Cameron English and Dr. Chuck Dinerstein on Episode 95 of the Science Dispatch podcast as they discuss:

This may sound strange but on some level antiviral drug research is "easy." Make that "easy compared to other therapeutic areas," because those who do research in the antiviral field – something I did for 10 years – have an advantage over scientis

I will soon be writing about the possibility of the first-ever direct-acting antiviral drug (DAAD) for respiratory syncytial virus (RSV), courtesy of Enanta Pharmaceuticals, a Massachusetts biotech company spe

Drug Coverage’s Carrot and Stick